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Abstract
The small RNA molecules of about 19-22 nucleotides in length, aptly called microRNAs, perform the task of gene
regulation in the cell. Interestingly, till the early nineties very little was known about them but eventually, the
microRNAs have become forefront in the area of research. The huge number of microRNAs plus each one of them
targeting a vast number of related as well as unrelated genes makes them very interesting molecules to study. To
add to the mystery of miRNAs is the fact that the same miRNA can have antagonizing role in two different cell
types i.e. in one cell type; the miRNA promotes proliferation whereas in another cell type the same miRNA inhibits
proliferation. Another remarkable aspect of the microRNAs is that many of them exist in clusters. In humans alone,
out of 721 microRNAs known, 247 of them occur in 64 clusters at an inter-miRNA distance of less than 5000bp.
The reason for this clustering of miRNAs is not fully understood but since the miRNA clusters are evolutionary con-
served, their significance cannot be ruled out. The objective of this review is to summarize the recent progress on
the functional characterization of miR-23a~27a~24-2 cluster in humans in relation to various health and diseased
conditions and to highlight the cooperative effects of the miRNAs of this cluster.
Introduction
MicroRNAs (miRNAs) are non-coding RNAs which are
initially transcribed from genomic DNA to long primary
transcripts (pri-miRNAs) and then are cleaved by
nuclear Drosha into 60-70 nucleotide hairpin-shaped
precursor RNAs (pre-miRNAs) [1,2]. Pre-miRNAs are
exported to the cytoplasm by Ran-GTP and Exportin-5
[3,4]. Once in the cytoplasm, the pre-miRNAs are
cleaved by dicer into 22 nucleotide mature miRNA
duplexes [5,6]. In association with RNA-induced silen-
cing complex (RISC), one strand of the miRNA duplex
binds to the target mRNA sequence in the 3’UTR
(untranslated region). This binding finally leads to either
the translational repression or degradation of the target
mRNA.
The first micro RNA (lin-4) was found in C. elegans in
1993 [7] and since then thousands of miRNAs have
been discovered in different species. In humans alone,
721 miRNAs have been identified till date [8]. Out of
these, 247 miRNAs have been found to occur in 64 clus-
ters at an inter-miRNA distance of less than 5000bp [8]
and since most of these clusters show a higher degree of
evolutionary conservation [9], it indicates that the clus-
tering propensity of miRNAs might be mediating biolo-
gical role. miRNAs are encoded in diverse genomic
locations including intergenic regions, introns of pro-
tein-coding genes and introns/exons of noncoding RNA
genes [8]. Literature suggests that a single miRNA can
regulate many mRNA targets, and several miRNAs can
r e g u l a t eas i n g l em R N A .T h e ya r ei n v o l v e di nav a r i e t y
of functions, including developmental transitions, neuro-
nal patterning, apoptosis, adipogenesis metabolism and
hematopoiesis in different organisms. Many independent
s t u d i e sh a v ep r o v i d e de v i d e n c ef o rt h ep o s s i b l ea s s o c i a -
tion of miRNA(s) with several human malignancies and
infectious diseases [10-12].
The miR-23a~27a~24-2 cluster is found to have
altered expression in many diseased states (Table 1).
This cluster has been shown tog i v er i s et oc o n t r a s t i n g
phenotypes in different cell types [13,14]. Several studies
have also linked the expression of this cluster to cell
cycle, proliferation, differentiation, haematopoesis and
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indicating that miR-23a~27a~24-2 cluster controls sev-
eral processes during health and diseases. Infact, this
cluster was the first downstream miRNA target impli-
cated in regulating the development of myeloid versus
lymphoid cells [18]. It is well documented that all three
miRNAs of this cluster are derived from a single pri-
mary transcript but depending on different biological
conditions their expression pattern varies i.e. in some
instances all three have similar expression pattern and
i ns o m eo n eo rt w oo ft h e s em i R N Aa r ee x p r e s s e da n d
the third is not (Table 1). Such complex expression pat-
tern and association with diseased states makes it a very
interesting subject for research. The objective of this
review is to summarize the current knowledge about the
miRNAs of miR-23a~27a~24-2 cluster in relation to
various health and diseased conditions and to highlight
the cooperative effects of the miRNAs of this cluster.
miR-23 cluster paralogs
Ancient gene duplications have given rise to miR-23
cluster paralogs in mammals: miR-23a~27a~24-2 cluster
(localized on chromosome 9q22) is intergenic and its
paralog miR-23b~27b~24-1 cluster (localized on chro-
mosome 19p13) is intronic. It is not uncommon for
miRNA clusters to have homologs and paralogs as
shown by Yu et al in 2006 [19]. The miR-23a~27a~24-2
cluster encodes pri-miRNA transcript composed of 3
miRNAs: miR-23a, miR-27a and miR-24. Mature
sequence of miR-23a and miR-27a differ by just one
nucleotide in comparison to their paralogs miR-23b and
miR-27b while the mature sequence of miR-24-1 and
miR-24-2 is same. Since the mature sequence of paralo-
gous miRNA is similar, one might speculate that they
have overlapping targets. The miRNA target prediction
software, TargetScan does predict common targets of
miR-23a and miR-23b and miR-27a and miR-27b, and
there are also reports where both the isoforms (27a &
27b or 23a & 23b) are simultaneously up regulated and
down regulated (Table 1). The targets may be shared
but since the paralogous clusters are present on differ-
ent chromosomes and are produced from different tran-
scripts, their regulation might be independent of each
other. Hence, the functional differences between them
would be because of differential regulation of their
expression and processing rather than different portfo-
lios of their potential targets [20]. Such duplication of
miRNA cluster would lead to very rigid control of the
targets of this cluster. But to decipher why such duplica-
tion occurred in the first place, one needs to study the
evolution of this cluster. To understand the evolution of
miR-23a and -23b clusters, we looked for their presence
in different organisms (Fig. 1a, Additional File 1). We
observed that these clusters are known to be present
only in vertebrates and there are certain differences
across species which are easily seen in the Additional
File 1. However, very extensive study needs to be done
to work out the evolution of these clusters. One such
study has been done for miR-17 cluster which has 3
paralogous cluster, one each on chromosome 7, 13 and
× by Tanzer et al in 2004 [21]. They have described
DDC (duplication-degeneration-complementation)
model for the evolution of miR-17 cluster which pre-
dicts that after a gene duplication either one of the two
paralogs is lost or, if both are retained, then the two
paralogs will evolve to perform complementary sub-
functions. The model further predicts that duplicate
clusters that still contain redundant miRNAs should dif-
fer in their spatio-temporal expression patterns. Extra-
polating these findings on miR-23a and miR-23b cluster,
Table 1 The pathological conditions in which miRNAs of
miR-23a~27a~24-2 cluster are implicated [102] (u - up,
d - down, u/d - up in one study and down in another,
NA - up/down is not known)
Diseased condition 23a 27a 24 23b 27b Reference
Acute lymphoblastic leukemia
(ALL)
uuu uu[ 2 8 ]
Acute myeloid leukemia (AML) u u u u u [28]
Acute promyelocytic leukemia
(APL)
d d d [41]
Autism spectrum disorder (ASD) d d [103]
Bladder cancer u u [42]
Breast cancer u [15,50]
Cardiac hypertrophy u u u u u [17,104]
Colorectal cancer d d u d [33,105]
Gastric cancer (stomach) u u u [32,33]
Glioblastoma u u u [106]
Heart failure u u u [107]
Hepatocellular carcinoma (HCC) u u u [13]
Kidney cancer u [108]
Lung cancer u d [109]
Lupus nephritis [110]
Malignant melanoma d d [111]
Oral squamous cell carcinoma
(OSCC)
d d d [112]




Prostate cancer u/d u/d u u/d u/d [115,116]
Schizophrenia d [117]
Serous ovarian cancer u u u [118]
Ulcerative colitis (UC) u u u [119]
Uterine leiomyoma (ULM) u u [120]
Vesicular stomatitis NA [121]
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were retained that differ in their expression profiles and
perform complementary functions.
The expression consistency of miRNAs in a miR-23
cluster has been shown in several studies (Table 1) but
the cooperativity between them is yet to be worked out.
Consistent with these studies, there is also a report
which shows that miRNAs of a miRNA cluster might
work in combination to accomplish their function [22].
Nevertheless, inconsistent expression of the miRNA
members of miR-23 cluster has also been observed. Yu
et al found miR-23a/23b cluster to be inconsistent while
studying human miRNA clusters in six hematopoietic
cell lines [19]. There was no detectable expression of
miR-23b, miR-27b and miR-24 in all 6 cell lines (3D5,
Jurkat, K562, CMK, HL-60, U937) but miR-23a and
miR-27a was detected with similar expression levels in 4
cell lines (3D5, K562, HL-60, U937). This may be caused
by their independent transcription or because they are
transcribed together but processed by additional post
transcriptional regulation mechanism.
Regulation of the miRNA cluster
The primary transcript of miR-23a~27a~24-2 cluster is
around 2.2 kb long [23]. It has been observed that miR-
23a~27a~24-2 cluster gene lacks long open reading
frame and the short open reading frame found does not
code for any protein. Lee et al in 2004 showed for the
first time that like protein-coding genes, the transcrip-
tion of miR-23a~27a~24-2 cluster can be Pol II depen-
dent [23]. Infact the region covering -603 and +36 bp
contains the promoter of miR-23a~27a~24-2 cluster. It
was also observed that the promoter of miR-
23a~27a~24-2 cluster lacks both the known common as
well as less common promoter elements such as TATA
box, the initiator element, the downstream promoter
element (DPE), or the TFIIB recognition element (BRE),
downstream core element (DCE), and the MED-1 (mul-
tiple start site element downstream) [24]. It is not sur-
prising as more than 80% of mammalian protein coding
genes are driven by TATA less promoter. The nucleo-
tide sequence of the promoter shows that the region
covering -530 to -410 of the cluster is GC rich and con-
tains at least two GC boxes and probably this is the site
where transcription factor (s) binds [25]. They also
observed that the miR-23a~27a~24-2 promoter is differ-
ent from the promoters of RNA pol II transcribed
snRNA genes as it lacks the proximal sequence element
(PSE) too.
The schematic structure of miRNA cluster along with
the promoter binding region has been shown in Fig. 1b.
Interestingly, even after the primary transcript of
miRNA cluster is made, there is no guarantee that all
three miRNAs will be formed proportionally. Previously,
in a study done by our group we have observed
increased expression of miR-27a as well as miR-24-2 but
Figure 1 Multispecies alignment and genomic organization of miR-23a~27a~24-2 cluster. a. Alignment of the mature sequences of miR-
23a, miR-27a and miR-24 among five species indicate that these miRNAs are highly conserved. b. The structure of the 2159 nucleotide pre-miR-
transcript of hsa-mir-23a~27a~24-2, the structure of individual miRNAs shown is derived from the Mfold program [101]http://mfold.bioinfo.rpi.
edu/cgi-bin/rna-form1.cgi with the input of their respective precursor sequences. The promoter region of this cluster spanning -603 to +36 is
well characterized; it includes a GC rich region (-530 to -410) where transcription factors are predicted to bind and the transcription start site
(TSS) spans 0 to 124 region. The poly-A tail is from 1752 to 1757.
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23a~27a~24-2 cluster in HEK293T cells [14]. In support
to our findings there are reports in the literature. Buck
et al also recently observed that down-regulation of
miR-27a occurs independently from miR-23a and miR-
24 [26]. In an independent study, Lee et al had
previously observed a block in the processing of pri-
miR-23a to mature miR-23a in HEK293 cells but not in
HeLa cells and undifferentiated P19 cells [27]. Moreover
inconsistent expression of the miRNA members of miR-
23 cluster has also been observed. It seems that both
transcriptional and post transcriptional mechanisms
could be responsible for differential expression of miR-
NAs located within the same genomic cluster. All this
indicates that the miRNAs of this cluster are under
complex regulatory mechanisms which can act even
after the primary transcript of miR-23a~27a~24-2 has
been made.
Functions of the miR-23a~27a~24-2 cluster
miR-23a~27a~24-2 cluster in tumorigenesis
Deregulation of microRNA(s) has been found in wide
range of human diseases including cancer. However, it
is not clear whether the observed change in the expres-
sion profile is a cause or consequence of pathological
processes. Additionally, miRNA profiling studies have
revealed that in various diseased conditions, all the three
microRNAs of the miR-23a~27a~24-2 cluster are simul-
taneously deregulated (Table 1). Although, their signifi-
cance is yet to be worked out in these conditions, but
the simultaneous increase or decrease of mir-23a, miR-
27a and miR-24-2 point towards their cooperative role
in carrying out their functions in the diseased condi-
tions. Expression of miR-23a~27a~24-2 cluster has been
found to be up-regulated in acute lymphoblastic leuke-
m i a[ 2 8 ] ,a c u t em y e l o i dl e u k e m i a[ 2 9 ] ,c h r o n i cl y m p h o -
cytic leukemia [30], breast cancer [31], gastric cancer
[32,33], cholangiocarcinoma cells [34] and hepatocellular
carcinoma cells (HCC) [13] as compared to their respec-
tive normals. In accordance with the tumorigenic activ-
ity, Huang et al in 2008 found that over expression of
miR-23a~27a~24-2 cluster could promote HCC cell
growth and attenuate TGF-b-induced apoptotic cell
death [13]. It has been observed that progressive tumors
show high CDK2/4 activity, which could phosphorylate
and inhibit the transcriptional activity of SMAD3, thus
conferring cancer cells to escape from TGF-b -i n d u c e d
tumor suppression. Recently, Rogler et al in 2009 [35]
has reported miR-23b cluster targets Smad 3, 4, and 5.
The coordinate targeting of Smad3 mRNA by miR-23a
cluster and miR-23b cluster adds an evolutionary advan-
tage. Generally individual miRNAs have a weak role in
knocking down gene expression [36,37] and an amplifi-
cation scheme may be necessary to bring a complex and
powerful signaling network such as TGF-b to a rapid
halt [38]. In addition to the above, the role of miR-
23a~27a~24-2 cluster has also been observed in metas-
tasis and liver cirrhosis [13]. Cameron et al observed
elevated expression of miR-23a, miR-24 and miR-27a in
type III versus type I EBV (Epstein-Barr virus) latency
[39]. The authors suggested that EBV-mediated regula-
tion of cellular miRNAs may contribute to EBV signal-
ing and might be associated with lymphoid and
epithelial cancers. Table 1 lists the diseases where these
miRNA have been implicated.
In contrast to the above cited studies on the wide-
spread evidence of the increased expression of
23a~27a~24-2 cluster in various cancers, recently we
observed that the over expression of miR-23a~27a~24-2
cluster in human embryonic kidney cells (HEK293T
cells) induces apoptosis by caspase-dependent as well as
caspase-independent pathway. Pro and anti-apoptotic
nature of the miR-23a~27a~24-2 cluster suggest that
this cluster may exhibit context-dependent functions
and warrants urgent need to identify its molecular func-
tions in humans, especially the downstream targets of
this cluster.
Function of the individual members of the miR-
23a~27a~24-2 cluster
miR-23a
miR-23a is the first member of the mir-23a~27a~24-2
cluster. So far, miR-23a has been implicated in several can-
cers, cardiac hypertrophy and muscular atrophy (Fig. 2).
miR-23a in cancer During cancer, oncogenic transcrip-
tion factor c-Myc regulates the glutamine catabolism in
addition to the regulation of cell cycle and glucose
metabolism. Myc’s role in stimulating glutamine catabo-
lism has been, in part attributed through the repression
of miR-23a and miR-23b. miR-23b originates from miR-
23b~27b~24-1 cluster and has one nucleotide difference
i nt h em a t u r es e q u e n c ei nc o m p a r i s o nt ot h em a t u r e
sequence of miR-23a. Gao et al in 2009 observed that
increase in c-Myc in human P-493 B lymphoma cells
and PC3 prostate cancer cells leads to suppression of
miR-23a/b which in turn results in greater expression of
their target protein, mitochondrial glutaminase, which is
required for bioenergetics, nucleotide biosynthesis and
redox homeostasis in cancer cells [40]. Saumet et al in
2008 observed that miR-23a~27a~24-2 is directly
repressed by the PML-RARA oncogene [41]. The PML-
RARA oncogene is formed by the chromosomal translo-
cation that fuses the gene encoding the retinoic acid
receptor alpha (RARA) with the promyelocytic leukemia
protein (PML) gene. This fused PML-RARA oncogene is
associated with acute promyelocytic leukemia (APL) and
is responsible for increasing the expression of key cancer
proteins in APL.
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regulation of miR-23a has been observed in cancers. Sig-
nificant up-regulation of miR-23a (and miR-27a) was
reported by Meng et al in human bladder cancer [42]
and by Gottardo et al in malignant cholangiocytes in
comparison to their normal tissues [34]. Furthermore,
Mi et al in his study showed that miR-23a along with
miR-24 and miR-27a are also among several other miR-
NAs that have been differentially expressed between
acute myeloid leukemia (AMLs) and acute lymphoblastic
leukemia (ALLs) [28]. Apart from these, up-regulation
of miR-23a/b along with miR-24 has also been reported
in osteoblast cell line [43].
Although the increase/decrease of miR-23a has been
reported in most of the studies related to cancer but it
is as yet unknown whether it is a cause or effect of the
disease. Apart from playing a role in cancer metabolism,
selective expression of miR-23a along with miR-24 has
been shown in microvascular endothelial cells in vivo
[44]. Also, miR-23a may play a role in angiogenesis as it
is among the highly expressed miRNAs in human umbi-
lical vein endothelial cells (HUVECs) [45]. It seems that
a re-evaluation of cancer metabolism considering gluta-
mine catabolism along with selective expression of miR-
NAs in the vasculature is needed before cancer can be
effectively targeted in therapy.
miR-23a in cardiac hypertrophy Cardiac hypertrophy
is thickening of heart muscle resulting in decrease in
size of the ventricles. It occurs in response to stress con-
ditions like hypertension, the heart muscle damage and
is an early indication of most of the heart diseases
[46,47]. Lin et al in their study reported that miR-23a is
a pro-hypertrophic miRNA, and its expression is regu-
lated by the transcription factor, nuclear factor of acti-
vated T cells (NFATc3) [17]. They found that NFATc3
could directly activate miR-23a expression through the
transcriptional machinery. Interestingly the muscle spe-
cific ring finger protein 1 (MuRF1), an anti-hypertrophic
protein, has been identified as a target of miR-23a. It
seems miR-23a conveys the hypertrophic signal by sup-
pressing the translation of MuRF1. It was also observed
that it is only miR-23a and not miR-27a and miR-24
which participate in initiating hypertrophy induced by
hypertrophic stimuli including isoproterenol and
Figure 2 Role of hsa-miR-23a in various pathological conditions. During cancer, repression of miR-23a by MYC leads to up-regulation of
glutaminase (GLS) thus mediating glutamine metabolism which is important for bioenergetics and maintaining redox homeostasis in cancer
cells. The transcription factor NFATc3 induces miR-23a which down-regulates MURF1, an anti-hypertrophic protein leading to cardiac
hypertrophy. Also, in the conditions of heat induced stress, the expression level of miR-23a increases and by down-regulating MAFbx (an
atrophic factor), it provides resistance to muscle atrophy.
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NAs clustered with miR-23a, miR-27a and miR-24
occurred much later. It was suggested by the authors
that since miR-23a is located closer to the transcription
start site (TSS), the effect must be reaching the miR-23a
first and later to other miRNAs.
miR-23a in muscle atrophy Skeletal muscle atrophy is
observed in many physiological and pathological settings
including fasting, several chronic diseases like cancer,
d i a b e t e s ,A I D S ,s e p s i s ,a n ds a r c o p e n i a .D u r i n ga t r o p h y ,
atrophic factors up-regulate the muscle-specific F-box
protein MAFbx/atrogin-1. Wada et al in 2008 observed
that miR-23a plays anti-atrophic effect. It has been
observed that miR-23a suppresses MAFbx/atrogin-1
translation by binding to 3’ UTR of the mRNA and
forced expression of miR-23a in myotubes and myofi-
bers results in resistance to muscle atrophy [48].
The control of genes with antagonizing functions [car-
diac hypertrophy (increased cell growth) and muscle
hypertrophy (reduced cell growth)] may underlie the
complex and conflicting effects of miR-23a.
miR-27a
miR-27a is the microRNA sandwiched between the miR-
23a and miR-24-2. Its paralogue, miR-27b originates from
miR-23b~27b~24-1 cluster. Some of the cellular targets of
miR-27a are those that can impact cell cycle regulation,
proliferation, apoptosis and differentiation (Fig. 3)
miR-27a in cancer and multidrug resistance of cancer
Oncogenic role of miR-27a is confirmed by several
experimental studies. miR-27a is significantly up-regu-
lated in renal cell carcinoma [42], in cervical cancer
[49], in gastric adenocarcinoma [32] and in breast can-
cer [15,50]. miR-27a is also involved in Helicobacter
pylori induced infection and gastric cancer [51]. It has
been found that in gastric cancer cells, miR-27a pro-
motes the tumor development by targeting a tumor sup-
pressor prohibitin, an evolutionary conserved and
ubiquitous protein interacting with pRb and its family
members [32]. In breast cancer cells, miR-27a functions
as an oncogene by indirectly enhancing the expression
of specificity protein (Sp) transcription factors. Sp fac-
tors have also been found to be over expressed in
tumours where they contribute to the proliferative and
angiogenic phenotype associated with cancer cells by
regulating number of angiogenic proteins like vascular
endothelial growth factor (VEGF), VEGF receptor 1
(VEGFR1, Flt-1), VEGFR2 (KDR) and the antiapoptotic
gene survivin [52-55]. miR-27a down-regulates the
repressor of the Sp proteins, ZBTB10/RINZF (a putative
zinc finger and BTB domain containing protein) in both
MDA-MB-231 breast cancer cells [15] and SKBr3 breast
cancer cells [56].
miR-27a also contributes to oncogenesis by regulating
cell cycle progression. It was observed that inhibition of
miR-27a increased the percentage of cells in G2-M
phase. This arrest was attributed to the induction of
Myt-1 [15], which is responsible for phosphorylation of
CDC2 resulting in inhibition of CDC2/cyclin B depen-
dent initiation of mitosis [57-59]. The study by
Chintharlapalli et al in 2009 showed that repression of
miR-27a leading to the induction of ZBTB10 and Myt-1
was the cause behind apoptotic and anti-carcinogenic
activity of Methyl 2-cyano-3,11-dioxo-18b-olean-1,12-
dien-30-oate (CDODAMe) in colon cancer cells [60].
Guttilla et al had shown in 2009 that miR-27a along
with miR-96, and miR-182 down-regulates FOXO-1
protein, a transcription factor that orchestrates the regu-
lation of genes involved in the apoptotic response, cell
cycle checkpoints, and cellular metabolism [50]. These
three microRNAs, miR-27a, miR-96 and miR-182, were
observed to be highly expressed in MCF-7 breast cancer
cells, in which the level of FOXO1 protein is very low.
It was also observed that over expression of FOXO1
resulted in decreased cell viability because of inhibition
of cell cycle traverse and induction of cell death. It
seems that targeting of FOXO1 by microRNAs may
contribute to transformation or maintenance of an
oncogenic state in breast cancer cells.
Apart from suppressing ZBTB10/RINZF and FOXO-1,
miR-27a contributes to oncogenesis by negatively regu-
lating RYBP/DEDAF, an apoptotic facilitator as has been
reported in SKBr3 cells [56].
In addition to the oncogenic activity, miR-27a also
regulates multidrug resistance. In two separate studies,
it was shown that the down-regulation of miR-27a leads
to decrease in the expression of multidrug resistance
gene (MDR1/P-glycoprotein/ABCB1) [61,62]. Down-reg-
ulation of miR-27a also caused a decrease in Bcl-2
expression and increase in the Bax expression, thereby
leading the cancerous cells towards apoptosis [62]. Also,
Sun et al showed that genistein significantly inhibited
growth of uveal melanoma cells and affects miR-27a and
target gene expression [63]. Very recently van Jaarsveld
et al has found significant association between miR-27a
and chemotherapy resistance in ovarian cancer [64].
Furthermore while studying the effect of SNPs in miR-
NAs, Yang et al in their study found that the SNP
rs895819, located in the terminal loop of pre-miRNA-
27a, showed a protective effect in a large familial breast
cancer study [65]. They also show that artificial muta-
tions in the terminal loop of miR-27a can block the
maturation process of the miRNA. They hypothesized
that the G-variant of rs895819 might impair the matura-
tion of the oncogenic miR-27a and thus, is associated
with familial breast cancer risk. In an independent
study, significant association between miR-27a poly-
morphism and gastric mucosal atrophy has been
observed in Japanese male subjects [66].
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sion of hsa-mir-27a in a sub-group of patients with very
poor prognosis [67].
miR-27a in osteoarthritis pathological process The
effect of miR-27a on overall regulation of matrix metal-
loprotease-13 (MMP-13) and insulin-like growth factor
binding protein (IGFBP), two genes involved in osteoar-
thritis (OA) pathophysiology adds another level of com-
plexity to miR-27a mediated gene regulation. Tardif et
al in their study showed that miR-27a indirectly
decreases both matrix metalloprotease-13 (MMP-13)
and the insulin-like growth factor binding protein
(IGFBP) [68]. Since MMP-13 degrades a wide range of
matrix components and IGFBP-5 plays an important
storage role for anabolic factor IGF-1, this regulation by
miR-27a could open up novel avenues in OA therapeu-
tic strategies.
In addition to the regulatory role of miR-27a in
diverse processes, miR-27a has also been associated with
viral infections. It has been observed that both host and
virus contain mechanisms to regulate miRNA expression
and/or activity [26].
miR-27a in differentiation miR-27a has been identified
as a negative regulator of adipocyte differentiation in a
study by Kim et al in 2010 [69]. It has been observed
that the expression of miR-27a decreases during adipo-
genesis while expression of peroxisome proliferators-acti-
vated receptor-gamma (PPARg) increases during
adipogenesis. Lin et al in an independent study showed
that miR-27a block the transcriptional induction of
PPARg and C/EBPa [70]. Since PPARg has been impli-
cated in the pathology of numerous diseases (including
obesity, diabetes, atherosclerosis and cancer) and miR-27a
has been found to suppress PPARg; it appears that miR-
27a could be a novel therapeutic target against metabolic
complications associated with obesity as well as cancer.
In another study, Ben-Ami et al observed that miR-
27a attenuates the expression of transcription factor
Figure 3 Importance of hsa-miR-27a in oncogenesis, proliferation and differentiation. miR-27a induces oncogenesis by negatively
regulating FOXO1 (transcription factor that regulates genes involved in apoptosis and cell cycle progression), RYBP (pro-apoptotic gene) and
ZBTB10 (repressor of Sp proteins which are known to cause proliferative and angiogenic phenotype in cancer cells), mediates differentiation by
down regulating RUNX1 (regulator of haematopoesis) and PPARg and also promotes proliferation by targeting RYBP (pro-apoptotic gene).
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expression of RUNX1, a lineage-specific gene expression
regulator has been found to increase during megakaryo-
cyte differentiation. It seems that there exists a feedback
loop mechanism between miR-27a and RUNX1 during
megakaryopoiesis as the RUNX1 binding sites have been
found upstream of miR-27a and the increase in miR-27a
expression has been concomitantly found with the bind-
ing of RUNX1 to miR-27a [71].
miRNA 27a has also been found to play a critical role
during osteogenesis. Schoolmeesters et al in their study
in 2009 observed that grancalcin (GCA), a regulator of
osteogenesis in human mesenchymal stem cells (hMSC)
is a target of miR-27a [72]. It was also observed that
expression of miR-27a decreases upon osteogeneic
differentiation.
miR-27a regulates fat metabolism and cell prolifera-
tion Ji et al in 2009 observed that miR-27a along with
miR-27b were up-regulated in activated Hepatic stellate
cells (HSCs). Under normal conditions HSCs reside in
the space of Disse, containing bunches of vitamin A-
riching lipid droplets and upon activatation HSCs lose
cytoplasmic lipid droplets and trans-differentiate to pro-
liferative, fibrogenic myofibroblasts, and play an essential
role in the formation of liver fibrosis. It was also
observed by the authors that down-regulation of over-
expressed miR-27a and 27b allowed activated HSCs to
accumulate cytoplasmic lipid droplets leading to
decreased HSCs proliferation. They also observed that
the fatty acid metabolism and cell proliferation regulat-
ing properties of miR-27a and miR-27b maybe, at least
partly mediated by affecting RXRa expression [73]. It
has been documented that RXRa plays a central role in
adipogenesis, probably as a heterodimeric partner for
peroxisome proliferator-activated receptor. RXRa also
suppresses DNA synthesis and causes cell growth arrest
in a variety of cell types including HSCs.
miR-24
miR-24-2 is unique among miRNAs of this cluster since
miR-24 can originate from two different genomic loci
one localized on chromosome 19p13 encoding miR-23b,
-27b, and -24-1, and the other localized on chromosome
9q22 encoding miR-23a, -27a, and -24-2.
Since, mir-24-1 and miR-24-2 have the same mature
sequence but different primary transcripts, it means that
they have similar biological functions but both of them
are differentially expressed and regulated. A number of
targets of miR-24 have been validated and its role in
various diseases have been studied (Fig. 4).
miR-24 in haematopoetic differentiation miR-24 is
among many miRNAs which have been found to play a
profound role in haematopoetic differentiation. Wang et
al in 2008 reported that miR-24 targets human activin
type I receptor ALK4 (hALK4) and modulates
erythropoeisis. Activin in cooperation with erythropoie-
tin plays an important role in differentiation of erythroid
progenitors. Activin binds to type II activin receptor,
leading to the recruitment, phosphorylation, and activa-
tion of type I activin receptor (ALK4, also known as
ActRIB). The activated ALK4 phosphorylates SMAD2
a n dS M A D 3 ,w h i c h ,u p o np h o sphorylation, form a het-
erocomplex with Co-SMAD (SMAD4), and the resulting
SMAD complex binds to the promoter of the target
genes, and regulates their expression. The authors show
that miR-24 down-regulated hALK4 and attenuated the
transcriptional responses of activin [74].
In a separate study, Lal et al in 2009 observed that
miR-24 regulates the histone variant H2AFX, a key dou-
ble-stranded break (DSB) repair protein during post
mitotic differentiation of hematopoietic cell lines [16].
The reduction in miR-24 levels correlate with enhanced
H2AFX mRNA and protein levels. Increased miR-24
levels have been found during differentiation while
diminished miR-24 levels have been found in primary
human blood cells. Moreover, it has also been observed
that miR-24-mediated suppression of H2AFX renders
cells hypersensitive to gamma-irradiation and genotoxic
drugs.
miR-24 in tumorigenesis Both the miR-24 loci (9q and
1 9 p )a r es h o w nt ob ef r e q u e n t l ya l t e r e di no r a ls q u a -
mous cell carcinoma (OSCC). Recently, Lin et al (2010)
found that miR-24 was up-regulated in OSCC tissues,
plasma and OSCC cell lines in comparison to normals.
The authors also observed that miR-24 might be contri-
buting to the growth of OSCC cells by targeting p57
(KIP2), a member of the KIP (kinase inhibitory protein)
family of CKI, a potential tumor suppressor gene [75].
Several reports in the literature show that miR-24
might function differently in different cells. miR-24 pro-
motes proliferation of transforming growth factor b-
treated hepatocellular carcinoma cells (HuH7) as well as
A549 lung carcinoma cells and inhibits proliferation in
HeLa cells [76]. miR-24 promotes proliferation by indir-
ect suppression of CHEK1 (which participates in G2-M
checkpoint), BRCA1 (that activates double-strand break
repair), CDKN1B (cyclin D inhibitor, p27Kip1) and VHL
(tumor suppressor gene). Previous study by Lal et al
further strengthened the proliferative function of miR-
2 4w h e r et h e yh a v es h o w nt h a tm i R - 2 4d i r e c t l ys u p -
presses CDK inhibitor p16INK4A which arrests cells in
the G1 phase [77]. It is well known that over expression
of Fas-associated factor-1 (FAF-1) stimulates apoptosis
and down-regulation contributes to tumorogenesis. Qin
et al showed that miR-24 can be a potential target for
gene and drug therapy to treat hormone insensitive
prostate cancer cells as they observed that increase of
FAF-1 after miR-24 down-regulation induced significant
apoptosis in DU-145, HGC-27, MGC-803 and HeLa
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Page 8 of 16cells [78]. Also, the anti-apoptotic role played by miR-24
might aid in cellular proliferation.
Anti-proliferative activity of miR-24 can be attributed
through the regulation of multiple targets of cell cycle.
Lal et al showed that miR-24 suppresses several key
genes that regulate cell-cycle progression like MYC and
E2F2 and several genes downstream of E2F2 and MYC
i.e., AURKB, CCNA2, CDK4, CDC2 and FEN1 [79].
Additionally, they have also shown that MCM4,
MCM10, RRM2 and PCNA are indirectly down-regu-
lated by miR-24. Moreover it was observed that in addi-
tion to HepG2 and K562 cells this anti-proliferative
effect can also be seen in human diploid fibroblasts.
Another level of miR-24 regulation in cell cycle pro-
gression came to light when Takagi et al found that
miR-24 down-regulates the expression of HNF4a,a
transcription factor regulating endo/xenobiotic-metabo-
lism [80]. The down-regulation of HNF4a by miR-24
resulted in the decrease of various target genes such as
cytochrome P450 7A1 and 8B1 as well as decrease of
the S phase population in HepG2 cells. They also
observed that the levels of miR-24 increase in HepG2
cells when treated with PMA, a protein kinase C/
mitogen-activated protein kinase (PKC/MAPK) activator
and H2O2, reactive oxygen species (ROS) generator.
Since activation of PKC pathway induces cholestasis
[81] and ROS pathway has a role in steato-hepatitis [82]
and in both the diseases HNF4a is down-regulated
[83-85], they inferred that this could be because of
induction of miR-24.
Another role of miR-24 where they contribute to
tumorigenesis was shown by Mishra et al. They showed
that miR-24 regulates expression of the dihydrofolate
reductase (DHFR), a key enzyme in intracellular folate
metabolism and target of methotrexate (MTX), an
important chemotherapeutic agent widely used in the
treatment of several malignancies [86]. It was observed
that a miR-24 target site polymorphism in DHFR 3’
UTR results in loss of miR-24-function and high DHFR
levels in the cell imparts a growth advantage to immor-
talized cells and induces neoplastic transformation.
Enough evidence is there to say that miR-24 is deregu-
lated in human colorectal cancer tumors and a subset of
tumors has reduced levels of miR-24. These results are
consistent with the data reported by Wu et al [87].
Their experiments indicated reduced expression of miR-
Figure 4 Involvement of hsa-miR-24 in biological processes and the diseased states. The different biological processes and the diseased
states where the role of hsa-miR-24 has been established are shown. The experimentally validated target genes of miR-24 are depicted along
with the respective biological processes.
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observed that miR-24 is a key factor for the induction of
anion exchanger-1 (AE1). Functional AE1 is an ery-
throid-specific integral membrane protein expressed on
the surface of mature erythrocyte. Under normal condi-
tions full length AE1 is silenced at protein level in other
tissues and has been found to impact the differentiation
of erythroid lineage cells. AE1 mediates the Cl
-/HCO3
-
exchange across the plasma membrane, regulates intra-
cellular pH and interacts with ankyrin, protein 4.1, spec-
trin which comprise the erythrocyte cytoskeleton.
Increased expression of AE1 has been found in the cyto-
plasm in gastric and adenocarcinoma. AE1 interacts
with another mir-24 target tumor suppressor p16 and
sequesters p16 in the cytoplasm, thereby leading to loss
of control of cell-cycle regulation and induction of gas-
tric carcinogenesis. Transfection of a miR-24 into gastric
cancer cells reduced the elevation of the AE1 protein,
which resulted in return of AE1-sequestrated p16 to the
nucleus, thereby inhibiting proliferation of the cells. The
undetectable expression of AE1 in K562 cells suggested
that miR-24 may take part in the tumorigenesis of ery-
throleukemia by arresting erythroid maturation through
silencing of AE1 expression.
mir-24 emerged as a biomarker specific for Kaposi
S a r c o m a( K S )i nas t u d yd o n eb yO ’Hara et al in 2009
to identify specific miRNAs that serve as biomarkers for
tumor progression [88]. Apart from differentiation, pro-
liferation and cell cycle regulation, miR-24 has also been
f o u n dt ob ea m o n gt h em i R N A sw h i c ha r eH o d g k i n
lymphoma (HL) specific [89]. Recently, Liu et al in 2010
identified it as the differentially expressed miRNA
involved in HCV entry, replication and propagation [90].
miR-24 in phenotypic plasticity Phenotypic plasticity is
essential for vascular development and vascular remo-
deling after injury as well as vascular proliferative
diseases like atherosclerosis, pulmonary arterial hyper-
tension etc. In response to injury, vascular smooth mus-
cle cells (vSMCs) undergo phenotypic modulation from
quiescent contractile phenotype to a proliferative
synthetic state. Transforming growth factor-b (TGFb)
and Bone morphogenetic protein (BMP) pathways
stimulate contractile phenotype whereas PDGF (platelet-
derived growth factor)-signaling pathway promotes syn-
thetic pathway. Recently Chan et al in 2010 observed
that miR-24 is a key regulator of the crosstalk between
the pro-contractile TGFb/BMP signal and the pro-
synthetic PDGF signal. The authors observed that hat
PDGF-BB induces miR-24, which in turn leads to down-
regulation of Tribbles-like protein-3 (TRIB3) [91].
Repression of TRIB3 coincides with reduced expression
of SMAD proteins and decrease in BMP and TGFb sig-
naling, promoting a synthetic (proliferative) phenotype
in vascular smooth-muscle-cell (vSMC) rather than
quiescent (contractile) phenotype. Inhibition of miR-24
by antisense oligonuclotides abrogates the down-regula-
tion of TRIB3 as well as pro-synthetic activity of the
PDGF-signaling pathway.
Biological relevance of miR-23a~27a~24-2 cluster as
revealed by bioinformatic analysis
The overall cellular functions and pathways affected by
co-expressed miRNAs remains largely undiscovered due
to lack of high throughput target validation methods and
such studies mostly rely on computational analysis of
potential mRNA targets. Hence, most of the research on
miRNAs to date has focused on individualistic effects of
am i R N A .H o w e v e r ,t h e r ea r es t i l laf e wr e p o r t sw h i c h
suggest that the miRNAs in a miRNA cluster effectively
cooperate by targeting the individual genes of the same
pathway thus justifying their coexistence [22,92]. To
reveal biological significance of miR-23a~27a~24-2
cluster, a list of predicted targets of miR-23a, miR-27a
and miR-24 was made using the TargetScan program,
miRNA target prediction software (Additional File 2)
[93,94]. From this list, we discovered that although the
t h r e em i R N A so ft h i sc l u s t e rshared very few predicted
mRNA targets (Table 2) but still all the three miRNAs
were reported either up-regulated or down-regulated
simultaneously in several pathological states (Table 1);
thereby indicating a possible connection between their
target mRNAs.
To evaluate the specific pathways or processes that are
targeted by the miRNAs of this cluster, we used the list
f r o mT a r g e t S c a np r o g r a mt of i n de n r i c h e dp a t h w a y sb y
GeneCodis [95,96] and PANTHER analysis [97]. The
PANTHER analysis revealed many signaling pathways as
the enriched categories (Fig. 5, Additional File 3). In
Table 2 The common genes among the predicted target





ADAM19 ADAM metallopeptidase domain 19 (meltrin beta)
ADAMTS6 ADAM metallopeptidase with thrombospondin type 1
motif, 6
CSNK1G1 Casein kinase 1, gamma 1
EBF3 Early B-cell factor 3
KPNA3 Karyopherin alpha 3 (importin alpha 4)
LIMK2 LIM domain kinase 2
NCOA1 Nuclear receptor coactivator 1
NLK Nemo-like kinase
PLEKHH2 Pleckstrin homology domain containing, family H (with
MyTH4 domain) member 2
RAP1B RAP1B, member of RAS oncogene family
SOCS6 Suppressor of cytokine signaling 6
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Page 10 of 16Figure 5 Workflow for the bioinformatics analysis of predicted targets of miR-23a, -27a and -24. Overview of the bioinformatics analysis
of the TargetScan predicted targets of hsa-miR-23a, hsa-miR-27a and hsa-miR-24. The list of the pathways which crossed the p-value < 0.01 in
PANTHER analysis is given in Additional File 3 and which crossed the p-value < 0.01 in GeneCodis analysis is given in Additional File 4. The
pathways highlighted in yellow came out to be common among the enriched pathways of both PANTHER and GeneCodis analysis.
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several diseases viz., colorectal cancer, pancreatic cancer,
renal carcinoma, chronic myeloid leukemia, acute mye-
loid leukemia and glioma are among the statistically sig-
nificant enriched categories (Fig. 5, Additional File 4). It
is noteworthy that the differential expression of miR-
23a, miR-24-2 and miR-27a has already been reported
in many of these diseased states (Table 1).
Interestingly, we observed that the Wnt, MAPK, TGF-
b pathways, Insulin signaling, T cell receptor signaling
and cytoskeletal regulation were the enriched categories
(p-value < 0.01) in both PANTHER and GeneCodis ana-
lysis. There are a few reports which have talked about
the involvement of miRNAs of this cluster in both
MAPK signaling [98,99] and TGF-b signaling
[13,91,100]. Since we got Wnt signaling as the enriched
pathway in the similar bioinformatic analysis for all
three miRNAs separately also (data not shown); we tried
to illustrate the cooperativity of miRNAs of this cluster
in regulating Wnt signaling (Fig. 6).
Wnt-b-catenin signaling controls critical events in
development, and its dysregulation leads to cancers and
developmental disorders. In normal circumstances, b-
catenin protein is under the inhibitory effect of GSK-3b
which leads to its degradation but when the Wnt signal-
ing proteins bind to its receptors Frizzled and LRP-5
and -6; it leads to the activation of disheveled protein.
This protein is an inhibitor of GSK-3b,t h u sp r e v e n t i n g
Figure 6 Speculated role of miR-23a~27a~24-2 cluster in regulation of Wnt Signaling. In normal circumstances, b-catenin protein is under
the inhibitory effect of GSK-3b which leads to its degradation but when the Wnt signaling proteins bind to its receptors Frizzled and LRP-5 and
-6; it leads to the activation of disheveled protein. This protein inhibits GSK-3b, thus preventing the degradation of b-catenin. Once the b-catenin
is stabilized, it translocates to the nucleus and regulates the gene expression. In the various pathological conditions where this cluster is over
expressed as is the case in many cancerous tissues, the Wnt genes; WNT3A and WNT4 could be targeted by miR-27a and miR-24 respectively,
LRP5 and LRP6 by miR-23a and miR-27a respectively and FZD4 and FZD7 are targeted by both miR-23a and miR-27a. This leads to the
inactivation of DVL1 protein. Also, DVL1 could itself be down-regulated by miR-27a. As a result, GSK-3b causes degradation of b-catenin, thus
preventing its translocation to the nucleus and ultimately the transcription. To conserve the cells energy resources b-catenin associated genes
like Cyclin D (targeted by miR-23a) and TCF7 (targeted by miR-24) are also inhibited. Among the other inhibitors of b-catenin (APC, Axin and
PP2A), APC is targeted by miR-23a and PP2A by miR-27a, maybe these inhibitors are not required once GSK-3b is there to degrade b-catenin.
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Page 12 of 16the degradation of b-catenin. The stable b-catenin
moves to the nucleus and regulates the gene expression.
A ss h o w ni nF i g .6t h ev a r i o u sg e n e si n v o l v e di nW n t
s i g n a l i n gp a t h w a ym a yb et a r g e t e db yt h em i R N A so f
the miR-23a~27a~24-2 cluster. If that is the case then
this cluster would lead to degradation of b-catenin
resulting in blockage of transcription. It is remarkable
that a few genes of the Wnt pathway are targeted by
more than one miRNA thus indicating strong associa-
tion among miRNAs and their stringent regulation of
the pathway.
This in-silico analysis implies that the miRNAs pre-
sent in this cluster could complement each other in reg-
ulating a certain pathway. Although, the targets used for
this study are bioinformatically predicted and not vali-
dated, Further characterization of the functional interac-
tion between Wnt signaling/b-catenin and miRNAs of
miR-23a~27a~24-2 cluster will be required to clarify the
role of miR-23a~27a~24-2 cluster in regulating Wnt
signaling.
In many studies, individual effect of a miRNA may
appear to be small but when they cooperate, the effect
can be of significant proportions. The cooperativity
among miRNAs is thus an interesting area of study and
can change our perception of how we look at the
miRNA mediated gene regulation.
Conclusions
miRNAs are complex molecules and since they target a
host of genes, their functions in a cell type are highly
dependent on the repertoire of the genes present in that
cell. In one type of cell, a miRNA can act as an apopto-
tic factor and in another the same miRNA can act as
proliferation promoting factor. The fact that the miR-
NAs can be under the control of other genes further
adds to their complexity. For instance, Kong et al
recently reported that the miR-23a~27a~24-2 transcript
i sad o w n s t r e a mt a r g e to fP U . 1a n dt h i sc l u s t e ri st h e
causal factor behind PU.1 promoting the myeloid differ-
entiation over lymphoid differentiation [18]. As a result,
it is highly improbable to characterize the functions of
miRNAs and annotate them as yet. So far, most of the
research in miRNA has been focused on the role of
individual miRNA on regulating a particular gene. But,
it is quite imperative to study the cooperative effects of
miRNAs on regulating a cellular pathway or deciding
the fate of a cell. This insight will give us a holistic pic-
ture of the miRNA regulation in the cell. The miRNAs
present together in a cluster seems the most obvious
subject to decipher the cooperative effects of miRNAs.
There are a few reports in the literature which talk
about cooperation among miRNAs in clusters. Yuan et
al. have investigated the extent of coordination of miR-
NAs in regulating protein-protein interaction network
[22]. They have shown that clustered miRNAs jointly
regulate proteins which lie in close proximity in the
interaction network. Kim et al have added a new dimen-
sion to this by reporting that separate clusters can also
be co-expressed and have related activities [92]. Herein,
we have discussed the individual functions of miRNAs
of miR-23a~27a~24-2 cluster that have been experimen-
tally validated and looked at their role in cooperation
with each other. For studying the cooperative effects of
miRNA in the cluster, we obtained the list of predicted
targets of miR-23a, miR-27a, and miR-24 from TargetS-
can and used them for discovering enriched pathways.
The analysis revealed the various enriched pathways and
diseases, thus justifying their occurrence together in a
single transcript and under the control of a single pro-
moter. Although, this bioinformatic analysis needs to be
validated experimentally, such a study would go a long
way in the understanding of miRNA clusters. The study
of miRNAs in coordination with each other is a must if
we want to exploit miRNAs for therapeutic purposes.
Additional material
Additional file 1: Presence/Absence of miRNAs of the two
paralogous clusters in vertebrates. The presence/absence of miRNAs
(-23a, 27a, -24, -23b, -27b) in vertebrates as indicated in miRBase is
represented in a table.
Additional file 2: Predicted targets of hsa-miR-23a, hsa-miR-27a and
hsa-miR-24 by TargetScan. This file contains the list of targets of hsa-
miR-23a, hsa-miR-27a and hsa-miR-24 as predicted by the TargetScan.
The union of the targets of these three miRNAs is used for bioinformatic
analysis as reported in the manuscript.
Additional file 3: Enriched pathways from PANTHER analysis.T h i s
file contains the list of enriched pathways obtained using PANTHER
analysis that satisfies the criteria of p-value < 0.01.
Additional file 4: Enriched pathways from GeneCodis analysis.T h i s
file contains the list of enriched pathways obtained using GeneCodis
analysis that satisfies the criteria of p-value < 0.01.
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